uTRACE®
Curasight's uTRACE® is a uPAR-PET imaging based diagnostic technology. It is used to find, visualize, and predict whether cancer is aggressive and, if so, how it should be treated. It serves as the companion diagnostics for uTREAT® and enables a true theranostic approach by supporting patient selection, confirming tumor targeting, and de-risking therapeutic development through human imaging validation.
uTRACE® is fully developed and GMP-manufactured and has been evaluated in nine clinical trials including 450 patients across eight different solid tumor types. A commercial supply infrastructure is in place.
PET imaging
PET imaging – Positron Emission Tomography – is one of the fastest-growing technologies in modern medicine and has truly revolutionized cancer care. It is a functional imaging technique that uses radioactive substances, known as radiotracers, to visualize and measure changes in metabolic processes and other physiological activities. The substance used by Curasight's uTRACE® for imaging targets and binds to uPAR, enhancing visualization of cancer.
The left side shows an MRI scan, where the white part in the centre shows a cancer tumour in this patients brain. The right side shows an image using Curasight'sTRACE® uPAR-PET imaging technology. The red area is where there is most activity, giving a more exact diagnose of the cancer and possibility to choose a treatment specific to this patient.
uPAR-PET scan of a prostate cancer patient using the uTRACE® technology. To the left a CT scan. To the right the fused uPAR-PET scan has been fused with the CT scan. The red arrows point to the prostate gland/tumor. The high uptake on the uPAR-PET indicates that this may be an aggressive cancer.
